聚焦审评审批新政,迎接药物研发创新的最好时代——《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》专家解读

• 机 构: 《药学进展》编辑部,
• 出 处: 药学进展
• 发表日期: 2017年10期
• 关键词: 审批制度 药品医疗器械 药品审评 药品研发 创新药物 临床试验 伦理委员会 医药企业 专家观点 药学进展

针对中共中央办公厅、国务院办公厅于2017年10月8日联合印发并实施的《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》(以下简称《意见》),征集《药学进展》编委中来自医药企业、科研单位、政府机构、CRO、临床研究机构等不同领域的专家的真知灼见。旨在从多个角度对《意见》进行深入分析和专业解读,加深行业人士对《意见》的理解。

In response to the “Opinions on Deepening the Innovation of Medical Device Innovation to Promote the Review, Examination and Approval System Reform” (hereinafter referred to as the “Opinions”) jointly issued by the General Office of the CPC Central Committee and the General Office of the State Council on October 8, 2017, Editorial Board from the pharmaceutical companies, research institutes, government agencies, CRO, clinical research institutions and other experts in different fields of insight. It aims to conduct in-depth analysis and professional interpretation of “opinions” from multiple perspectives and deepen the understanding of industry professionals about “opinions.”